Group 1 - The core issue involves the investigation of Jiang Wei, a major shareholder and actual controller of Haohai Biological Technology, by the China Securities Regulatory Commission for suspected insider trading [1] - The investigation pertains solely to Jiang Wei as an individual and does not involve the company's stock or daily operations, indicating no significant impact on the company's regular business activities [2] Group 2 - On May 7, Haohai Biological Technology's stock closed at 53.17 yuan per share, down 0.21%, with a market capitalization of 12.4 billion yuan [3] - The company recently announced a stock buyback, having repurchased approximately 1.49 million A-shares, accounting for 0.64% of the total share capital, with a total transaction amount of about 85.94 million yuan [3] - For the fiscal year 2024, Haohai Biological Technology reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, a year-on-year increase of 1.04%, indicating stagnation in growth [3] - The overall gross margin decreased from 70.46% to 69.89%, despite the increasing revenue share from high-margin hyaluronic acid products, due to significant price declines in other products [3] Group 3 - In Q1 2025, Haohai Biological Technology reported total revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit attributable to shareholders of 90.31 million yuan, down 7.41% [4] - The decline in performance reflects intense competition in the hyaluronic acid and medical aesthetics market, with emerging alternative materials reshaping the landscape [4] - Research indicates that recombinant collagen may replicate the success of hyaluronic acid, supported by continuous improvements in supply chain policies and technological breakthroughs [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） * 僅供識別 证券代码：688366 证券简称：昊海生科 公告编号：2025-021 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於公司控股股東、實際控制人之一收到中國證券監督管理委員會立案告知書的公 告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年5月7日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執 行 ...

Core Viewpoint - Several listed companies in the Shanghai and Shenzhen markets announced significant developments, including share buybacks, acquisitions, and changes in shareholding structures, which may present investment opportunities and insights into market trends [2]. Group 1: Share Buybacks - Kweichow Moutai repurchased a total of 934,800 shares in April 2025, amounting to 1.44 billion yuan, representing 0.0744% of its total share capital, with a maximum purchase price of 1,575 yuan per share [3] - As of the end of April 2025, Kweichow Moutai has repurchased 2.0175 million shares, accounting for 0.16% of its total share capital, with a total expenditure of 3.039 billion yuan [3] Group 2: Acquisitions - Hainan Development signed an agreement to acquire 51% of Wangying Technology for no more than 450 million yuan, aiming to transition into a digital economy service provider [4] - Qingdao Beer plans to acquire 100% of Jimo Yellow Wine for 665 million yuan, which will enhance its product line and market channels in the fermented beverage sector [8] Group 3: Shareholding Changes - Yonggui Electric announced that independent director Liu Jian was placed under detention, but this matter does not involve the company directly [5] - Haohai Biological's controlling shareholder Jiang Wei is under investigation for insider trading, which is not expected to impact the company's operations [6] - Zhongchao Holdings experienced a stock price fluctuation, with its actual controller Yang Fei selling 0.11% of the company's shares during this period [7] Group 4: Shareholding Reductions and Increases - Pan-Asia Micro透 announced that shareholders Sai Fu Venture and Southern Precision plan to collectively reduce their holdings by up to 7% [9] - Xinya Da's actual controller and major shareholder plan to reduce their holdings by a total of 327,000 shares [10] - China Railway Industry's controlling shareholder plans to increase its stake in the company by 160 million to 300 million yuan, with a maximum increase of 2% of the total share capital [12]

Group 1 - The core point of the news is that Haohai Biological Technology (688366.SH) announced that its controlling shareholder, Jiang Wei, is under investigation by the China Securities Regulatory Commission for insider trading, which is unrelated to the company's stock [1] - The investigation pertains solely to Jiang Wei as an individual and will not significantly impact the company's daily operations [1] - As of May 7, Haohai Biological's stock price was 53.17 yuan, with a market capitalization of 12.399 billion yuan [1] Group 2 - Haohai Biological is a technology innovation company focused on the research, production, and sales of medical devices and pharmaceuticals using biomedical materials and genetic engineering technology [3] - The company aims to provide innovative medical products through technological innovation and resource integration, gradually achieving import substitution in related pharmaceutical products [3] - As of 2023, Haohai Biological has completed industry restructuring in biomedical materials and has achieved leading advantages in four main business areas: ophthalmology, plastic surgery and wound care, orthopedics, and anti-adhesion and hemostasis [3] Group 3 - For Q1 2025, Haohai Biological reported a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit attributable to shareholders of 90.3121 million yuan, down 7.41% year-on-year [3] - The company's basic earnings per share for the first quarter were 0.39 yuan [3] - As of May 7, the stock price of Haohai Biological had decreased by 0.21% [4]

关于公司控股股东、实际控制人之一收到中国证券 监督管理委员会立案告知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688366 证券简称：昊海生科 公告编号：2025-021 上海昊海生物科技股份有限公司 本次事项系对蒋伟先生个人的调查，其不参与公司日常经营管理，该事项不 会对公司日常经营活动产生重大影响。立案调查期间，蒋伟先生将积极配合中国 证监会开展调查工作。 公司将持续关注上述事项的进展情况，并严格按照有关法律法规的规定和要 求，及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 上海昊海生物科技股份有限公司董事会 2025 年 5 月 8 日 上海昊海生物科技股份有限公司（以下简称"公司"）收到控股股东、实际 控制人之一蒋伟先生通知，其于近日收到中国证券监督管理委员会（以下简称"中 国证监会"）出具的《立案告知书》（编号：证监立案字 0382025016 号），因涉嫌 内幕交易，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法 律法规，决定对其立案。据本公司了解，该事项 ...

昊海生科公告，公司控股股东、实际控制人之一蒋伟先生近日收到中国证券监督管理委员会出具的立案 告知书，因涉嫌内幕交易对其进行立案调查。该事项系对蒋伟先生个人的调查，不涉及公司股票，与公 司日常经营活动无关，不会对公司日常经营产生重大影响。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於召開2024年度暨2025年第一季度中英雙語業績說明會的公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年5月6日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執 行董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 证券代码：68836 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於第二期以集中競價交易方式回購公司A股股份的進展公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年5月6日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執行 董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 证券代码：688366 证券简 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 ...

FF301 呈交日期: 2025年5月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06826 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 39,141,840 | RMB | | 1 RMB | | 39,141,840 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 39,141,840 | RMB | | 1 RMB | | 39,141,840 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/ ...